請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54675
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賴美淑(Mei-Shu Lai) | |
dc.contributor.author | Shih-Ting Huang | en |
dc.contributor.author | 黃詩婷 | zh_TW |
dc.date.accessioned | 2021-06-16T03:36:32Z | - |
dc.date.available | 2018-06-01 | |
dc.date.copyright | 2015-09-14 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-06-09 | |
dc.identifier.citation | 1. WHO. Cardiovascular disease. 2013.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421. 3. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith SC, Jr., Levy D, Watson K and Wilson PW. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013. 4. 中央健康保險局. 全民健康保險藥品給付規定. 5. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D and Turner MB. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292. 6. 統計處. 民國102年死因統計年報 2014. 7. 行政院衛生署國民健康局. 2007年台灣地區高血壓、高血糖、高血脂之追蹤調查研究. 2011. 8. Rosenson RS. Statins: can the new generation make an impression? Expert opinion on emerging drugs. 2004;9:269-79. 9. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H and Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47. 10. Stamler J, Wentworth D and Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA : the journal of the American Medical Association. 1986;256:2823-8. 11. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA : the journal of the American Medical Association. 1984;251:351-64. 12. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA : the journal of the American Medical Association. 1984;251:365-74. 13. Navar-Boggan AM, Peterson ED, D'Agostino RB, Sr., Neely B, Sniderman AD and Pencina MJ. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015;131:451-8. 14. Rossouw JE, Lewis B and Rifkind BM. The value of lowering cholesterol after myocardial infarction. The New England journal of medicine. 1990;323:1112-9. 15. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM and Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. The New England journal of medicine. 1990;322:1700-7. 16. Wong ND, Wilson PW and Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Annals of internal medicine. 1991;115:687-93. 17. Ross R and Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science (New York, NY). 1973;180:1332-9. 18. Talwalkar PG, Sreenivas CG, Gulati A and Baxi H. Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV. Indian journal of endocrinology and metabolism. 2013;17:628-35. 19. Endo A, Kuroda M and Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. The Journal of antibiotics. 1976;29:1346-8. 20. Furberg CD and Pitt B. Withdrawal of cerivastatin from the world market. Current controlled trials in cardiovascular medicine. 2001;2:205-207. 21. Knopp RH. Drug treatment of lipid disorders. The New England journal of medicine. 1999;341:498-511. 22. Maron DJ, Fazio S and Linton MF. Current perspectives on statins. Circulation. 2000;101:207-13. 23. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78. 24. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J and Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. 25. Ramjee V, Eapen DJ and Sperling LS. Optimal lipid targets for the new era of cardiovascular prevention. Annals of the New York Academy of Sciences. 2012;1254:106-14. 26. Micromedex T, Village G and Colorado. DRUGDEXR System (electronic version). 27. Hartzema AG, Tilson HH and Chan KA. Pharmacoepidemiology and therapeutic risk management Harvey Whitney Books Co.; 2008. 28. Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P and Chinellato A. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. European journal of clinical pharmacology. 2007;63:197-203. 29. Wallach Kildemoes H, Vass M, Hendriksen C and Andersen M. Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health policy (Amsterdam, Netherlands). 2012;108:216-27. 30. Chiang CW, Chiu HF, Chen CY, Wu HL and Yang CY. Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiology and drug safety. 2008;17:62-9. 31. Lin YC, Yang CC, Chen YJ, Peng WC, Li CY and Hwu CM. Utilization of statins and aspirin among patients with diabetes and hyperlipidemia: Taiwan, 1998-2006. Journal of the Chinese Medical Association : JCMA. 2012;75:567-72. 32. Eissa A, Krass I and Bajorek BV. Use of medications for secondary prevention in stroke patients at hospital discharge in Australia. International journal of clinical pharmacy. 2014;36:384-93. 33. Kapral MK, Degani N, Hall R, Fang J, Saposnik G, Richards J, Silver FL, Robertson A and Bierman AS. Gender differences in stroke care and outcomes in Ontario. Women's health issues : official publication of the Jacobs Institute of Women's Health. 2011;21:171-6. 34. Sjolander M, Eriksson M and Glader EL. Few sex differences in the use of drugs for secondary prevention after stroke: a nationwide observational study. Pharmacoepidemiology and drug safety. 2012;21:911-9. 35. Aliprandi-Costa B, Ranasinghe I, Chow V, Kapila S, Juergens C, Devlin G, Elliott J, Lefkowitz J and Brieger DB. Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000-2007. The Medical journal of Australia. 2011;195:116-21. 36. Mangiapane S and Busse R. Prescription prevalence and continuing medication use for secondary prevention after myocardial infarction: the reality of care revealed by claims data analysis. Deutsches Arzteblatt international. 2011;108:856-62. 37. Vermeer NS and Bajorek BV. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. Journal of clinical pharmacy and therapeutics. 2008;33:591-601. 38. Garg P, Wijeysundera HC, Yun L, Cantor WJ and Ko DT. Practice patterns and trends in the use of medical therapy in patients undergoing percutaneous coronary intervention in Ontario. Journal of the American Heart Association. 2014;3. 39. Weng R. Drug utilization evaluation and therapeutic equivalence of statins. 臨床藥學研究所. 2007;碩士. 40. Safar P and Bachman L. Compliance of the lungs and thorax in dogs under the influence of muscle relaxants. Anesthesiology. 1956;17:334-46. 41. Haynes R, Brian. R, Sackett. and L. D. Medical Centre & Workshop/Symposium on Compliance with Therapeutic Regimens (1974 : McMaster University Medical Centre) Johns Hopkins University Press: Baltimore, MD 1976. 42. Sikka R, Xia F and Aubert RE. Estimating medication persistency using administrative claims data. The American journal of managed care. 2005;11:449-57. 43. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA and Wong PK. Medication compliance and persistence: terminology and definitions. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008;11:44-7. 44. Ho PM, Bryson CL and Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028-35. 45. Andrade SE, Kahler KH, Frech F and Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiology and drug safety. 2006;15:565-74; discussion 575-7. 46. DP. N. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence. . 47. Burkhart PV and Sabate E. Adherence to long-term therapies: evidence for action. Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing / Sigma Theta Tau. 2003;35:207. 48. Osterberg L and Blaschke T. Adherence to Medication. New England Journal of Medicine. 2005;353:487-497. 49. Mann DM, Allegrante JP, Natarajan S, Halm EA and Charlson M. Predictors of adherence to statins for primary prevention. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2007;21:311-6. 50. Perreault S, Dragomir A, Blais L, Berard A, Lalonde L, White M and Pilon D. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. European journal of clinical pharmacology. 2009;65:1013-24. 51. Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V and Kokia E. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clinical therapeutics. 2008;30:2167-79. 52. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, Santos RD, Verdejo J, Messig M, McPherson R, Seung KB and Tarasenko L. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28-34. 53. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC and Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA : the journal of the American Medical Association. 2002;288:455-61. 54. Foody JM, Joyce AT, Rudolph AE, Liu LZ and Benner JS. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Current medical research and opinion. 2008;24:1987-2000. 55. Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA and Shrank WH. The implications of therapeutic complexity on adherence to cardiovascular medications. Archives of internal medicine. 2011;171:814-22. 56. Ivers NM, Schwalm JD, Jackevicius CA, Guo H, Tu JV and Natarajan M. Length of initial prescription at hospital discharge and long-term medication adherence for elderly patients with coronary artery disease: a population-level study. The Canadian journal of cardiology. 2013;29:1408-14. 57. Halava H, Korhonen MJ, Huupponen R, Setoguchi S, Pentti J, Kivimaki M and Vahtera J. Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2014;186:E449-56. 58. Mann DM, Woodward M, Muntner P, Falzon L and Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. The Annals of pharmacotherapy. 2010;44:1410-21. 59. Lemstra M, Blackburn D, Crawley A and Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. The Canadian journal of cardiology. 2012;28:574-80. 60. Brown MT and Bussell JK. Medication adherence: WHO cares? Mayo Clinic proceedings Mayo Clinic. 2011;86:304-14. 61. Mauskop A and Borden WB. Predictors of statin adherence. Current cardiology reports. 2011;13:553-8. 62. Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ and Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. Journal of epidemiology / Japan Epidemiological Association. 2014;24:500-7. 63. Cheng CL, Kao YH, Lin SJ, Lee CH and Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiology and drug safety. 2011;20:236-42. 64. Gaziano JM, Hennekens CH, Satterfield S, Roy C, Sesso HD, Breslow JL and Buring JE. Clinical utility of lipid and lipoprotein levels during hospitalization for acute myocardial infarction. Vascular medicine (London, England). 1999;4:227-31. 65. Jackevicius CA, Mamdani M and Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA : the journal of the American Medical Association. 2002;288:462-7. 66. Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F and Collin J. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. British journal of clinical pharmacology. 2005;59:564-73. 67. Vinker S, Shani M, Baevsky T and Elhayany A. Adherence with statins over 8 years in a usual care setting. The American journal of managed care. 2008;14:388-92. 68. Chee YJ, Chan HH and Tan NC. Understanding patients' perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review. Singapore medical journal. 2014;55:416-21. 69. Glanz K, Rimer BK and Viswanath K. Health Behavior and Health Education: Theory, Research, and Practice, 4th Edition. Jossey-Bass; 2008. 70. Mann DM. Resistant disease or resistant patient: problems with adherence to cardiovascular medications in the elderly. Geriatrics. 2009;64:10-5. 71. Burnier M, Pruijm M, Wuerzner G and Santschi V. Drug adherence in chronic kidney diseases and dialysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2015;30:39-44. 72. Tandra S and Vuppalanchi R. Use of statins in patients with liver disease. Current treatment options in cardiovascular medicine. 2009;11:272-8. 73. Sandhu S, Wiebe N, Fried LF and Tonelli M. Statins for improving renal outcomes: a meta-analysis. Journal of the American Society of Nephrology : JASN. 2006;17:2006-16. 74. Cohen DE, Anania FA and Chalasani N. An assessment of statin safety by hepatologists. The American journal of cardiology. 2006;97:77c-81c. 75. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, Avorn J, Solomon D, Brookhart MA and Choudhry NK. Patient, physician, and payment predictors of statin adherence. Medical care. 2010;48:196-202. 76. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M and Turchin A. Discontinuation of statins in routine care settings: a cohort study. Annals of internal medicine. 2013;158:526-34. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54675 | - |
dc.description.abstract | 背景:
心血管疾病造成社會極大負擔,高血脂為其最主要危險因子。直至今日,利用statin藥品降血脂已有諸多臨床證據支持,且2013年ACC/AHA 準則建議在已發生心血管疾病的病人,應維持長期而有效的statin使用。然而,台灣新發心血管疾病族群中statin藥品的處方情況與遵囑性、持續性及其相關因子都仍未有相關證據。 目的: 本論文主要探討台灣新發粥狀動脈硬化心血管疾病族群statin藥品使用狀況及處方遵囑性、持續性隨時間變化情形,同時進一步分析影響處方遵囑性、持續性之相關因子。 材料與方法: 本論文以全民健康保險資料申報檔進行分析,選取2006到2012年新發粥狀動脈硬化心血管疾病且出院後90天內門診使用statin之病患做為研究族群,利用描述性分析statin藥品處方比例之年度趨勢,以及處方statin藥品後病人遵囑性、持續性隨時間改變情形,遵囑性以藥品覆蓋率及藥品持有率來定義、持續性以連續有處方天數不超過90天來定義。並利用廣義線性混合模型及cox proportional hazard model分別分析影響藥品遵囑性、持續性之相關因子。 結果: 第一部份、新發粥狀動脈硬化心血管疾病個案statin藥品使用分析 在2006年至2012年新發粥狀動脈硬化心血管疾病且出院後90天內門診使用statin個案,共189,545人次(173,235人),其中,年度別開方statin百分比自30%上升到43%。在statin種類的選擇上,以high potency的atorvastatin及rosuvastatin占大宗,從71%上升到83%;以處方劑量來看,雖然高劑量的statin藥品有逐年增加趨勢,但主要以處方中低劑量藥品為主,占總用藥的九成以上。 第二部份、statin藥品遵囑性、持續性及相關影響因子 排除在門診初次處方statin前即再次發生粥狀動脈硬化心血管疾病病人後,共185,252人次(169,624人)。藥品遵囑性部份,總追蹤七年共十五段180天,追蹤人次從185,252下降至398人次,覆蓋率及持有率皆在處方一年內下降最快。藥品持續性部份,在開始用藥一年、兩年、三年後分別有三成、五成、六成病人發生用藥不持續,追蹤七年後剩下三成病人持續使用statin。 進一步分析藥品遵囑性及藥品持續性的危險因子,跟藥品遵囑性相關的重要危險因子包括:年齡超過75歲、腎臟疾病、憂鬱症等病史、曾使用digitalis或胰島素等;保護因子包括:診斷為急性心肌梗塞 (有做CABG/PTCA處置)或穩定冠心症且接受CABG/PTCA處置、住院期間或住院前一年曾使用statin、高血脂病史、曾使用β-blocker, ARBs, antiplatelet、出院第一筆處方statin屬high potency、開方statin的醫療機構層級別高、處方科別為心臟科及內分泌科、處方年代較近等。 和藥品持續性相關的危險因子與保護因子和遵囑性類似,但在危險因子部份住院期間曾做血脂檢查、曾使用CCBs或口服降血糖藥、有失智症病史之病患較易不持續用藥,保護因子部份曾使用anticoagulants較易持續用藥。 結論: 雖然statin藥品在新發粥狀動脈硬化心血管疾病病人的使用近幾年有增加趨勢,但在處方比例上仍低,且病人使用statin藥品的遵囑性、持續性在用藥初期下降最快。建議未來可在用藥初期針對statin藥品的遵囑性、持續性高危險族群做介入,並評估相關措施的效益。 | zh_TW |
dc.description.abstract | Background:
Cardiovascular disease has caused great health burden, hyperlipidemia is the main risk factor. Clinical trials had demonstrated statin as the leading lipid-lowering drugs; moreover, ACC/AHA guideline also suggested long and effective statin use on known atherosclerotic cardiovascular disease (ASCVD) patients. However, statin prescription, utilization pattern, and risk factors associated with suboptimal utilization on newly onset ASCVD patients were unknown. Objective: To identify statin utilization pattern and time trend in patients with newly onset ASCVD in Taiwan and to explore factors associated with statin adherence and persistence. Material & Method: Patients with newly onset ASCVD covering the period between 2006 and 2012 who had prescribed statin at the outpatient department within 90 days after discharged are our target population. We analyzed the statin prescription, patient adherence, and patient persistence pattern. Adherence pattern was defined by proportion of days covered (PDC) and medication possession ratio (MPR); Persistence was defined as the final day of the last prescription filled prior to a gap in therapy of 90 days. Generalized estimating equation and cox proportional hazard model were used separately to establish potential risk factors to suboptimal statin adherence and persistence. Result: Part 1. Statin utilization analysis among newly onset ASCVD patients A total of 189,545 newly onset ASCVD episodes (173,235 person) were identified. Prescription rate of statin increased from 30% to 43%. Atorvastatin and rosuvastatin were prescribed most frequently. Although the prescription rate of high dose statins increased, moderate to low dose were used most frequently, accounting for over 90% of all prescriptions. Part 2. Statin adherence, persistence, and the associated factors We excluded those who had a second ASCVD event prior to the first statin prescription at the outpatient department after discharged, and ended up with 185,252 episodes (169,624 person). We followed these patients for seven years (segmented into fifteen 180-days intervals), and the follow-up episodes decreased from 185,252 to 398. Median PDC and MPR had decreased sharply within the first year of prescription. Regarding to the persistence, there were 30%, 50%, and 60% of patients turned out to be non-persistence after one, two and three year of statin use, and only 30% of patients remain persistence for the total seven years of follow up. Furthermore, we analyzed risk factors to suboptimal statin adherence and persistence. Main risk factors associated with suboptimal statin adherence including: age over 75 years old, history of renal disease, depression, medication history of digitalis or insulin; Protective factors including: diagnosis of acute myocardial infarction (with CABG/PTCA) or stable coronary artery disease receiving revascularization, statin use during or one year before ASCVD hospitalization, history of hyperlipidemia, medication history of β-blocker, ARBs, antiplatelet, high potency of the first statin prescription, higher level healthcare organization, prescription speciality of cardiology and endocrinology, more recent year of prescription. Factors associated with suboptimal statin persistence were almost the same as with suboptimal adherence. However, Patients with lipid examination during ASCVD hospitalization, medication history of CCBs or oral anti-diabetic drugs, and history of dementia were more likely to discontinue statin therapy, while those with anticoagulants history were more likely to be persistent. Conclusion: Although the prescription of statin agents on newly onset ASCVD population increased, the percentage of patients being treated remains low. Adherence and persistence to statin declined sharply within the first year of treatment. We suggest there should be some early interventions on high risk population as well as to evaluate the effect of such interventions in future study. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T03:36:32Z (GMT). No. of bitstreams: 1 ntu-104-R02849019-1.pdf: 1945658 bytes, checksum: 535c24f8f77881200b2ad0e25ba431b9 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 中文摘要 v
Abstract vii 第一章、 前言 1 第一節、 研究背景與動機 1 第二章、 文獻回顧 3 第一節、 心血管疾病與高血脂之相關研究 3 第二節、 降血脂治療之發展 5 第三節、 Statin藥品發展與降血脂效果 7 2.3.1 藥品發展與分類 7 2.3.2 降血脂效果 8 第四節、 Statin藥品使用分析之研究 11 第五節、 藥品遵囑性、持續性相關研究 14 2.5.1 藥品遵囑性、持續性之定義 14 2.5.2影響Statin藥品遵囑性、持續性相關因子之研究 15 第六節、 研究目的 19 第三章、 材料與方法 20 第一節、 研究設計 20 第二節、 資料庫來源 20 第三節、 建立研究資料庫之流程 21 3.3.1 第一部份:2006到2012年台灣新發ASCVD個案statin藥品使用 21 3.3.2 第二部份:statin藥品遵囑性、持續性及相關影響因子 22 3.3.3 建立研究族群流程 22 第四節、 研究變項及操作型定義 25 3.4.1 研究藥品變項 25 3.4.2 研究疾病變項 26 3.4.3 其它相關變項 26 第五節、 統計分析 29 3.5.1 模式設定 29 3.5.2 研究假說及統計方法 29 第四章、 研究結果 32 第一節、 第一部份:新發ASCVD個案statin藥品使用分析 32 4.1.1 新發ASCVD個案基本資料 32 4.1.2 新發ASCVD個案描述性分析 35 4.1.3 年度別statin藥品開立處方人次及種類、劑量之分析 39 4.1.4 出院初次處方statin藥品種類、劑量之分析 42 第二節、 第二部份:statin藥品遵囑性、持續性及相關影響因子 46 4.2.1 藥品遵囑性、持續性之分析 46 4.2.2 影響藥品遵囑性之相關因子 52 4.2.3 影響藥品持續性之相關因子 64 第五章、 結論與討論 70 第一節、 Statin藥品使用分析 70 第二節、 影響藥品遵囑性及持續性之相關因子 73 第三節、 優勢與限制 76 第六章、 結語與建議 78 參考文獻 79 | |
dc.language.iso | zh-TW | |
dc.title | 台灣新發粥狀動脈硬化心血管病人statin使用分析及相關影響因子探討 | zh_TW |
dc.title | Utilization pattern of statin among patients with newly onset atherosclerotic cardiovascular disease in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 邵文逸(Wen-Yi Shau),劉仁沛(Jen-Pei Liu),賴超倫(Chao-Lun Lai),林珍芳(Zhen-Fang LIn) | |
dc.subject.keyword | 粥狀動脈硬化心血管疾病,他汀類藥物,藥品使用,遵囑性,持續性,危險因子, | zh_TW |
dc.subject.keyword | ASCVD,statin,utilization,adherence,persistence,risk factors, | en |
dc.relation.page | 116 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-06-10 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 1.9 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。